Navigation Links
Transgenomic, Inc. Reports Second Quarter 2009 Results
Date:8/12/2009

both the six months ended June 30, 2008 and 2009. Excluding the impact of foreign currency revaluation gains/losses, operating expenses were down by $812,000 for the six months ended June 30, 2009 compared to the same period in 2008.

Comment and Outlook

Craig Tuttle, the Company's President and Chief Executive Officer, noted, "It is rewarding to see a sales rebound well above our first quarter results. While we have not quite reached quarterly sales at our former run rate prior to the economy decline, sales in second quarter did increase $500,000 above first quarter. In addition, we do see interest in new instrument sales opportunities throughout the remainder of this fiscal year and next year. Budget approval processing will drive the timing of these sales. We are seeing several new projects in our Pharmacogenomics lab which have the potential to move forward toward full clinical trial studies as well as a number of discovery projects with a similar outcome potential. As such, we are optimistic that sales will return to our 2008 levels within a quarter or two. In addition, with significant product launches targeted for the fourth quarter, notably our high sensitivity assay for KRAS mutations as well as our NuroPro assays for Alzheimer's and Parkinson's disease, we anticipate a return to year-over-year sales growth by next year. Equally positive, our Molecular Diagnostic Laboratory has grown to 62% in the six months ended June 30, 2009 compared to the same period in 2008. This growth rate remains below our full year 2008 growth which was 70% year-over-year. When the economic situation improves, we fully expect an improvement in the growth rate in our diagnostic testing net sales. In addition there will be impact related to the new assays being added."

Earnings Call

Company management will discuss second quarter 2009 financial results via teleconference on Wednesday, August 12th, at 5:00 p.m. Eas
'/>"/>

SOURCE Transgenomic, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Transgenomic, Inc. Announces Appointment of New Board Members
2. Transgenomic, Inc. Reports First Quarter 2009 Results
3. Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results
4. Transgenomic, Inc. Reports Third Quarter 2008 Results
5. Transgenomic, Inc. Forms Scientific Advisory Board
6. Transgenomic, Inc. Reports Second Quarter 2007 Results
7. BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results
8. Oncothyreon reports second quarter 2009 financial results
9. ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results
10. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
11. Dendreon Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... 2015 Regis Technologies, Inc. is ... chiral stationary phases (CSPs) for analytical and preparative ... and presenting solutions for new clients, Regis implemented ... valuable addition to its core expertise in chiral ... can tackle projects for the scale clients need–from ...
(Date:6/1/2015)... , ROCHESTER, Minn. and ... 2015 Baxter Ventures, the venture arm of ... Clinic and Velocity Pharmaceutical Development, LLC ("VPD") today announced ... a unique collaboration model initiated by Baxter Ventures to ... in the areas of immunology, hematology, and oncology. Following ...
(Date:6/1/2015)...  Berg, a biopharmaceutical company committed to uncovering health ... from its trials using its cancer drug BPM 31510 ... triple negative breast cancer, at the 51 st ... (ASCO), May 29 – June 2 in ... one of the first cancer drugs guided in development ...
(Date:6/1/2015)... 1, 2015  OncoSec Medical Inc. ("OncoSec") (NASDAQ: ... cancer immunotherapies, today announced a collaboration with University ... Medicine to test ImmunoPulse™ IL-12 as an immunotherapy ... goals of the canine study are to advance ... ImmunoPulse™ IL-12 and validate key clinical biomarkers. ...
Breaking Biology Technology:Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 2Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 3OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 2OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 3OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 4
... - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) announced today ... Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced ... Clinical Cancer Research. , , ... The paper covers final results from a Phase Ia/Ib U.K. ...
... , NINGBO, China , ... Equipment Co., Ltd. (TAIJI),s FGD (Flue-gas desulfurization),technology was officially ... For the project, TAIJI chose to use steel slag ... used in desulfurization. In,comparison to the use of lime ...
... May 18, 2010 Simbionix USA Corporation,the world,s leading provider ... industry, is proud to,report that their ANGIO Mentor virtual reality simulator was ... April 2010 for,the training and certification of vascular physicians from medical ... , ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research 2Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research 3Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research 4TAIJI Announces Official Operation of Its Sintering FGD Project for Tangshan 2Simbionix ANGIO Mentor Plays Important Role in Physician Training and Certification 2
(Date:5/19/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
(Date:5/14/2015)... DUBLIN , May 14, 2015 Research and ... addition of the "Fingerprint Sensors Market in Smart ... This report believes that 2014 was a watershed ... to Apple,s introduction of ,Apple Pay,. Apple gave fingerprint ... its mobile payment service. Fingerprint sensors are a must-have ...
(Date:5/11/2015)... 2015 Curemark LLC, a privately held drug ... new Phase III double blind, randomized, placebo-controlled clinical trial ... on all children ages 3-8 with Autism. Previously, Curemark ... double blinded clinical trial for CM-AT in children ages ... digestive enzyme chymotrypsin. This new trial will help determine ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... large-scale expansion of agriculture in the Amazon through deforestation ... study. Published today, 10 May, in IOP Publishing,s ... deforestation will not only reduce the capacity of the ... feedbacks that will decrease the productivity of pasture and ...
... San Diego, CA A large, multi-institutional research team involved ... analysis in the current issue of the journal Cell ... direct early human development. Led by Bing Ren of the ... Institute for Biological Studies and James Thomson of the Morgridge ...
... at St. Jude Children,s Research Hospital, has been selected ... is one of 27 scientists nationwide chosen for the ... HHMI investigators in the United States, and Dyer will ... St. Jude. Investigators selected for the program by ...
Cached Biology News:No-win situation for agricultural expansion in the Amazon 2Mapping the embryonic epigenome 2Mapping the embryonic epigenome 3St. Jude scientist named Howard Hughes Medical Institute investigator 2
... Building on over 20 years of ... for the Life Sciences, the Freedom EVO ... for expansion according to future needs. Together ... each system is equipped to successfully operate ...
... fixed-angle microcentrifuge rotor at RCF up ... filters consist of a membrane-containing filter ... filter by centrifugation for bacteria removal, ... of cells from media and DNA ...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. Material: ...
12 breakable polypropylene strips of 8 wells each held in a rigid frame. Ideal for antibody assays....
Biology Products: